A REVIEW OF COVID-19 TREATMENT
Mohamed Ashraf P. T.*
This review mainly focusing on antivirals and drugs with immune-modulatory, anti-inflammatory properties, against COVID-19, their pharmacological features and achievement in term of patients' clinical outcomes. The global pandemic of novel corona virus disease 2019 (Covid-19) caused by SARS-CoV-2 began in Wuhan, China, in December 2019, and has since spread worldwide. At the time of this review, COVID-19 has been diagnosed more than 6,485,526 cases and 386,704 death. A large number of antiviral agents, including lopinavir/ritonavir, favipiravir, remdesivir, many of which are used for the treatment of hepatitis, human immunodeficiency virus (HIV) and flu symptoms are currently using as off-label for the worldwide patients. The viral lifecycle, viral entry, and immune regulation pathway providing potential targets for drug therapy.
Keywords: Covid-19, cytokine storm, ARDS, Favipiravir, Remdesivir, Tocilizumab.
[Full Text Article]